Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$37.68 USD

37.68
3,255,904

+0.12 (0.32%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $37.68 0.00 (0.00%) 5:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

by Zacks Equity Research

Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

    Zacks Equity Research

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

    by Zacks Equity Research

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

      Zacks Equity Research

      J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?

      by Zacks Equity Research

      The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

        Zacks Equity Research

        Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

        by Zacks Equity Research

        Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

          Tracey Ryniec headshot

          What All Investors Should Know about Trade Deficits and Recessions

          by Tracey Ryniec

          What's the trade deficit really about? And what are the key signals that may alert investors to an upcoming recession?

            Zacks Equity Research

            Merck's Keytruda Offers Survival Benefit in Lung Cancer Study

            by Zacks Equity Research

            Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.

              Indrajit Bandyopadhyay headshot

              4 Drug/Biotech Stocks to Buy Ahead of World Health Day

              by Indrajit Bandyopadhyay

              Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.

                Zacks Equity Research

                Novartis Announces Data on Cardiovascular Drug Entresto

                by Zacks Equity Research

                Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.

                  Zacks Equity Research

                  Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study

                  by Zacks Equity Research

                  A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.

                    Zacks Equity Research

                    GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?

                    by Zacks Equity Research

                    As GlaxoSmithKline (GSK) starts a strategic review of Horlicks and other smaller nutrition products, a number of companies in the food & beverage industry are waiting to scoop it up.

                      Zacks Equity Research

                      Puma's Shares Fall This Year Post a Solid 2017: Here's Why

                      by Zacks Equity Research

                      Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.

                        Zacks Equity Research

                        Company News For Mar 28, 2018

                        by Zacks Equity Research

                        Companies in the news are: RHT,MKC,INFO,GSK,NVS

                          Zacks Equity Research

                          Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV

                          by Zacks Equity Research

                          Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.

                            Kinjel Shah headshot

                            4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

                            by Kinjel Shah

                            The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

                              Zacks Equity Research

                              Pfizer's Chantix Fails in Phase IV Study in Young Smokers

                              by Zacks Equity Research

                              Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

                                Zacks Equity Research

                                Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod

                                by Zacks Equity Research

                                Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.

                                  Zacks Equity Research

                                  GlaxoSmithKline Initiates Phase III Combo Study on Benlysta

                                  by Zacks Equity Research

                                  GlaxoSmithKline (GSK) initiates a phase III study evaluating Benlysta in combination with Rituxanin adult patients with systemic lupus erythematosus.

                                    Zacks Equity Research

                                    Pfizer's Xtandi Label Expansion Filing Gets Priority Review

                                    by Zacks Equity Research

                                    FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

                                      Zacks Equity Research

                                      Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus

                                      by Zacks Equity Research

                                      Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.

                                        Zacks Equity Research

                                        J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status

                                        by Zacks Equity Research

                                        The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.

                                          Zacks Equity Research

                                          Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

                                          by Zacks Equity Research

                                          Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

                                            Zacks Equity Research

                                            Merck's Keytruda Gets Priority Review for Cervical Cancer

                                            by Zacks Equity Research

                                            Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.

                                              Zacks Equity Research

                                              Gilead Announces Positive Data on New HIV Therapy Biktarvy

                                              by Zacks Equity Research

                                              Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.

                                                Zacks Equity Research

                                                Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

                                                by Zacks Equity Research

                                                Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.

                                                  Zacks Equity Research

                                                  5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018

                                                  by Zacks Equity Research

                                                  Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.